Chugai Pharmaceutical Co., Ltd.
4519.THealthcareTSEDrug Manufacturers - General · Last scanned May 30, 2026
Scan Results
Daily timeframeChugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. Valued at $12.99T, 4519.T is a mega-cap name in its sector. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody.
Market Cap
$12.99T
Beta
0.56
P/E (TTM)
29.94
P/E (Fwd)
33.45
EPS (TTM)
$263.59
EPS (Fwd)
$235.91
ROE
23.7%
ROA
17.4%
Cash
$850.09B
Total Debt
$0
Free CF
$308.22B
52W Change
2.1%
Annual Financials
Cash vs Debt
Chugai Pharmaceutical Co., Ltd. reports $850.09B in cash and $0 in total debt. Free cash flow comes in at $308.22B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 23.7% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 17.4% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $1.26T (2022) to $1.26T (2025).
With a beta below 0.7, Chugai Pharmaceutical Co., Ltd. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing 4519.T.